EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Pegvisomant in severe, treatment-resistant thyroid eye disease: a case report

Laura Köröskényi, Noémi Szkibák, Zita Steiber, Sándor Barna, Edit B Nagy, Zsolt Karányi, József Balla, Miklós Bodor, Endre V Nagy, Annamária Erdei

Drugs in Context · 12.10.2026 · 1

DOI: 10.7573/dic.2026-7-5 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Drugs in Context, online erschienen am 12.10.2026. Verfasst von Laura Köröskényi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Teprotumumab, a monoclonal antibody against the IGF1 receptor, has proven effective in the treatment of thyroid eye disease (TED). Pegvisomant reduces IGF1 levels through selective inhibition of growth hormone receptors. Here, we present a hypothesis-generating case of a 69-year-old patient with progressive TED. Pegvisomant 20 mg was administered daily for 90 days. IGF1 levels declined and remained low–normal during treatment. Clinical activity scores and VISA (vision, inflammation, strabismus and appearance) scores improved rapidly. MRI assessment showed that water content of both extraocular muscles and orbital connective tissue decreased after treatment. 99mTc-DTPA SPECT confirmed the decrease in disease activity. Further studies may confirm the efficacy of pegvisomant in TED. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-pegvisomant-in-severe-treatment-resistant-thyroid-eye-disease-a-case-report

Schlagwörter

Stichwörter der Autor:innen

IGF1growth hormone receptorpegvisomantthyroid eye disease

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Ophthalmology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Division of Nuclear Medicine, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Division of Radiology and Imaging Science, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Zitieren

APA

Köröskényi, L., Szkibák, N., Steiber, Z., Barna, S., Nagy, E. B., Karányi, Z., Balla, J., Bodor, M., Nagy, E. V., & Erdei, A. (2026). Pegvisomant in severe, treatment-resistant thyroid eye disease: a case report. Drugs in Context, 1. https://doi.org/10.7573/dic.2026-7-5

Vancouver

Köröskényi L, Szkibák N, Steiber Z, Barna S, Nagy EB, Karányi Z, et al. Pegvisomant in severe, treatment-resistant thyroid eye disease: a case report. Drugs in Context. 2026:1. doi:10.7573/dic.2026-7-5

BibTeX
@article{Krsknyi2026,
  author = {Köröskényi, Laura and Szkibák, Noémi and Steiber, Zita and Barna, Sándor and Nagy, Edit B and Karányi, Zsolt and Balla, József and Bodor, Miklós and Nagy, Endre V and Erdei, Annamária},
  title = {Pegvisomant in severe, treatment-resistant thyroid eye disease: a case report},
  journal = {Drugs in Context},
  year = {2026},
  pages = {1},
  doi = {10.7573/dic.2026-7-5}
}
Kostenlos starten →